Garren argues that the VEGF-Trap is every bit as good as Avastin with a better side-effect profile. He says the market is large enough to accommodate two blockbusters here. Your comments?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.